SR ONE CAPITAL MANAGEMENT, LLC

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Redwood City, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Sasha Keough, attorney-in-fact for SR One Capital Management, LLC
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for SR ONE CAPITAL MANAGEMENT, LLC

Form 4 holding 10%+ Owner

Arcellx, Inc.

Security class
Common Stock
Shares / value
1,658,780
Estimated value
$91,677,287
Report date
11 May 2023
Price
$55.27
Ownership
Indirect
Form 4 holding 10%+ Owner

eFFECTOR Therapeutics, Inc.

Security class
Common Stock
Shares / value
1,821,415
Estimated value
$1,104,688
Report date
27 Nov 2023
Price
$0.6065
Ownership
Indirect
Form 4 holding 10%+ Owner

Avalyn Pharma Inc.

Security class
Common Stock
Shares / value
1,122,087
Estimated value
Report date
01 May 2026
Price
Ownership
Indirect
Form 4 holding 10%+ Owner

Avalyn Pharma Inc.

Security class
Series C-1 Convertible Preferred Stock
Shares / value
0
Estimated value
Report date
01 May 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Avalyn Pharma Inc.

Security class
Series D Convertible Preferred Stock
Shares / value
0
Estimated value
Report date
01 May 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Odyssey Therapeutics, Inc.

Security class
Series A-2 Convertible Preferred Stock
Shares / value
0
Estimated value
Report date
11 May 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Odyssey Therapeutics, Inc.

Security class
Series A Convertible Preferred Stock
Shares / value
0
Estimated value
Report date
11 May 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Odyssey Therapeutics, Inc.

Security class
Series B Convertible Preferred Stock
Shares / value
0
Estimated value
Report date
11 May 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Odyssey Therapeutics, Inc.

Security class
Series C Convertible Preferred Stock
Shares / value
0
Estimated value
Report date
11 May 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Odyssey Therapeutics, Inc.

Security class
Series D Convertible Preferred Stock
Shares / value
0
Estimated value
Report date
11 May 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Odyssey Therapeutics, Inc.

Security class
Series D Warrants (Right to Buy)
Shares / value
0
Estimated value
Report date
11 May 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by SR ONE CAPITAL MANAGEMENT, LLC

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .